Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses

OWENSBORO, Ken­tucky (USA), SAN DIEGO, Cal­i­for­nia (USA) and MUNICH (Ger­many), May 07, 2012 — Ken­tucky Bio­pro­cess­ing, LLC (KBP), Icon Genet­ics, GmbH (ICON) and Mapp Bio­phar­ma­ceu­ti­cal, Inc. (Mapp­bio) have announced that they have entered into detailed nego­ti­a­tions aimed at merg­ing the com­pa­nies to cre­ate a sin­gle, ful­ly inte­grat­ed bio­phar­ma­ceu­ti­cal dis­cov­ery, devel­op­ment and man­u­fac­tur­ing enter­prise.

While many details of the pro­posed merg­er remain to be final­ized, the par­ties have agreed that any oper­at­ing head­quar­ters would remain at the KBP loca­tion in Owens­boro, Ken­tucky. KBP Chairman/CEO Hugh Hay­don would assume the posi­tion of CEO of the merged com­pa­ny. Drs. Vic­tor Klimyuk, Lar­ry Zeitlin, Kevin Wha­ley and Yuri Gle­ba along with KBP’s Bar­ry Bratch­er have all agreed to assume lead­ing posi­tions with­in the merged com­pa­ny.

The com­pa­nies have a six-year his­to­ry of suc­cess­ful col­lab­o­ra­tion. They have com­bined the unique intel­lec­tu­al prop­er­ty and research and devel­op­ment capa­bil­i­ties of ICON, the prod­uct dis­cov­ery exper­tise at Mapp­bio and the pro­duc­tion process devel­op­ment and large scale cGMP man­u­fac­tur­ing facil­i­ties and know-how at KBP to cre­ate a pipeline of mon­o­clon­al anti­bod­ies and oth­er bio­phar­ma­ceu­ti­cal prod­uct can­di­dates using a Nico­tiana plant-based pro­duc­tion sys­tem. The com­bined company’s intel­lec­tu­al prop­er­ty and know-how, R&D and man­u­fac­tur­ing capa­bil­i­ties, prod­uct pipeline as well as expe­ri­enced man­age­ment team will posi­tion the merged busi­ness as a lead­ing PMP based bio­phar­ma­ceu­ti­cal com­pa­ny.

KBP’s Hay­don said of the pro­posed merg­er: ”With the recent announce­ment by Pro­tal­ix of FDA approval of the first plant cell derived injectable bio­phar­ma­ceu­ti­cal, we believe that the time is right to more for­mal­ly inte­grate the impres­sive capa­bil­i­ties of each of our com­pa­nies to ful­ly lever­age the speed, flex­i­bil­i­ty and low­er costs asso­ci­at­ed with our plant-based pro­duc­tion sys­tem and to aggres­sive­ly devel­op sev­er­al advanced prod­ucts in our merged pipeline.”

Pre­clin­i­cal results of mon­o­clon­al anti­body prod­uct can­di­dates pro­duced by the com­pa­nies have shown greater effi­ca­cy and effi­cien­cy of action than sim­i­lar prod­ucts pro­duced through tra­di­tion­al fer­men­ta­tion sys­tems. Lever­ag­ing can­di­dates from their exist­ing pipeline the new com­pa­ny would antic­i­pate mov­ing as many as three prod­ucts into the clin­i­cal phase of devel­op­ment with­in a short time fol­low­ing the merg­er.

The par­ties hope to reach a defin­i­tive agree­ment in the com­ing months. Addi­tion­al details were not dis­closed.

About KBP (

KBP is a world leader in the expres­sion, extrac­tion, pro­cess­ing and purifi­ca­tion of bio­phar­ma­ceu­ti­cal pro­teins from plant-based sys­tems. Work­ing with a glob­al net­work of col­lab­o­ra­tors, KBP uti­lizes its tech­nol­o­gy, know-how and cGMP-capa­ble facil­i­ties to pro­duce bio­phar­ma­ceu­ti­cal pro­teins for research and devel­op­ment, as well as for pre-clin­i­cal and clin­i­cal appli­ca­tions.

About ICON (
Icon Genet­ics is cur­rent­ly a whol­ly owned sub­sidiary of Nomad Bio­science GmbH, Munich, Ger­many. The com­pa­ny dis­cov­ers and devel­ops new bio­phar­ma­ceu­ti­cals and high-val­ue pro­tein prod­ucts using green plants as pro­duc­tion hosts. ICON offers new plant man­u­fac­tur­ing tech­nolo­gies which address speed, yield, pre­ci­sion, expres­sion con­trol and safe­ty of prod­uct man­u­fac­tur­ing in plants. ICON oper­ates its own cGMP-com­pli­ant man­u­fac­tur­ing facil­i­ty in Halle, Ger­many. ICON’s own pipeline includes sev­er­al ‘bio­bet­ter’ anti-can­cer anti­bod­ies (pre-clin­i­cal stage).

About Mapp­bio (
Mapp Bio­phar­ma­ceu­ti­cal was found­ed in 2003 to devel­op nov­el phar­ma­ceu­ti­cals with an empha­sis on mon­o­clon­al anti­body ther­a­peu­tics. The com­pa­ny has a strong track record of iden­ti­fy­ing potent mon­o­clon­als and advanc­ing them through pre­clin­i­cal activ­i­ties with non-dilu­tive financ­ing. Mappbio’s port­fo­lio con­sists of prod­ucts for the pre­ven­tion and treat­ment of a range of dis­eases includ­ing C. dif­fi­cile, Ebo­la virus, and Res­pi­ra­to­ry Syn­cy­tial Virus (RSV) infec­tions.